BASF and Catalent join forces to solve bioavailability challenges
4 April 2012 | By Catalent Pharma Solutions
Catalent Pharma Solutions and BASF have entered into a broad collaboration...
List view / Grid view
News
UCB and Amgen initiate sclerostin antibody Phase 3 program in patients with Postmenopausal Osteoporosis
4 April 2012 | By Amgen
The start of sclerostin antibody Phase 3 clinical trial program announced...
Lonza appoints Richard Ridinger as new CEO
At a meeting on 2 April 2012, the Board of Directors of Lonza elected Mr. Richard Ridinger as the new CEO of Lonza. Mr. Ridinger will become CEO of Lonza effective 1 May. Rolf Soiron was acting CEO ad interim, since the end of January.
Tecan granted patent for revolutionary NanoQuant Plate™
3 April 2012 | By kdm communications limited
The revolutionary design of Tecan’s NanoQuant Plate™ has been recognized with the granting of a new European patent...
A case study by Catalent expert to be presented at PDA Annual Meeting
3 April 2012 | By Catalent Pharma Solutions
“Challenging Technical Transfer of a Biopharmaceutical – the Product X Case Study”...
GSK receives further data from phase lll studies of albiglutide in type 2 diabetes
3 April 2012 | By GlaxoSmithKline
Data from seven studies support progression towards regulatory filings...
Interview with Robert Mattes, Applications Scientist, FOSS NIRSystems
2 April 2012 | By FOSS NIRSystems
Freddy White, European Pharmaceutical Review speaks to Robert Mattes, Applications Scientist, FOSS NIRSystems...
Gerresheimer grows in the emerging markets and acquires Indian pharma glass manufacturer Neutral Glass
2 April 2012 | By Gerresheimer AG
Gerresheimer AG, is committed to growth in the emerging markets...
Teva announces launch of generic Avapro® and generic Avalide® in the United States
2 April 2012 | By Teva Pharmaceutical Industries Ltd
180-day period of marketing exclusivity awarded...
Novartis QVA149 Phase III COPD studies meet primary endpoints
2 April 2012 | By Novartis
QVA149 efficacy, safety and exercise endurance primary endpoints all met[1],[2],[3]...
Shionogi-ViiV Healthcare announces initial data from pivotal phase III study of dolutegravir in HIV
2 April 2012 | By GlaxoSmithKline
SPRING-2 study meets primary endpoint of non-inferiority of dolutegravir...
Efficacy and safety data for ZOSTAVAX®
2 April 2012 | By Merck
Merck announced that data from the pivotal Phase III study with ZOSTAVAX® in adults ages 50 to 59 were published in the April 1 issue of Clinical Infectious Diseases...
Amgen and AstraZeneca announce collaboration
2 April 2012 | By Amgen
Collaboration comprises five monoclonal antibodies brodalumab (AMG 827) Phase 3 trial planned in 2012...
Merial acquires Newport Laboratories
2 April 2012 | By Merial
Merial, the Animal Health division of Sanofi, announced that it has acquired Newport Laboratories...
Lilly targets faulty c-MET receptor in cancer research studies presented at AACR Meeting
2 April 2012 | By Eli Lilly and Company
Studies provided basis for ongoing Phase I, II studies in gastric, other cancers...
